10-Q: United Health Products Faces FDA Hurdles

United Health Products, Inc. reported continued net losses and significant regulatory challenges for its CelluSTAT hemostatic gauze, including an FDA Warning Letter and disapproval of a key clinical trial application.

Summary

• Reported a net loss of $1,846,846 for the six months ended June 30, 2025, compared to $883,959 for the same period in 2024.
• No revenues generated for the three or six months ended June 30, 2025 and 2024, as capital is focused on Class III PMA.
• Cash and cash equivalents significantly decreased to $225 as of June 30, 2025, from $168,883 at December 31, 2024.
• Negative working capital of $1,883,479 as of June 30, 2025.
• FDA disapproved the Investigational Device Exemption (IDE) application for a new 27-subject clinical trial, citing an unresolved Warning Letter from March 25, 2025, regarding five violations in the 2019 clinical trial.
• Disclosure controls and procedures were deemed "not effective" as of June 30, 2025.
• The Vice President of Finance and Principal Financial Officer resigned on June 12, 2025, with CEO Brian Thom assuming the interim Principal Financial Officer role.
• The company is exploring strategic options including a sale, merger, or commercial partnerships, and does not intend to pursue full commercialization independently.

Sentiment

Score: 2

Explanation: The company faces severe liquidity issues with minimal cash, recurring substantial losses, and a critical FDA Warning Letter that has directly halted its path to market for its key product. While the product shows promise and strategic options are being explored, the immediate operational and regulatory hurdles are significant and create substantial doubt about its ability to continue as a going concern.

Positives

• Net loss for the three months ended June 30, 2025, decreased to $315,187 from $432,021 in the prior year comparable period, primarily due to a decrease in operating expenses.
• Net cash used in operating activities for the six months ended June 30, 2025, decreased to $458,658 from $693,481 in the prior year, largely due to non-cash stock-based compensation.
• The company's CelluSTAT product has an existing FDA 510(k) approval for superficial use since 2012.
• Prior 2019 clinical trial showed statistically superior performance of CelluSTAT over Ethicon's Surgicel Original in time to hemostasis, with no adverse events attributable to the product.
• The company has been contacted by several medical technology companies expressing interest in its products and business strategy.

Negatives

• Recurring net losses, negative working capital, and insufficient revenue to cover operating expenses, leading to substantial doubt about the company's ability to continue as a going concern.
• Significant decrease in cash and cash equivalents from $168,883 at December 31, 2024, to $225 at June 30, 2025.
• Total liabilities increased to $3,252,090 at June 30, 2025, from $2,713,810 at December 31, 2024.
• Accumulated deficit worsened to $(80,547,789) at June 30, 2025, from $(78,700,943) at December 31, 2024.
• FDA issued a Warning Letter on March 25, 2025, identifying five violations in the 2019 clinical trial.
• FDA disapproved the IDE application for a new clinical trial on April 25, 2025, specifically citing the unresolved Warning Letter.
• Disclosure controls and procedures were deemed "not effective" as of June 30, 2025.
• Increased interest expense due to larger outstanding loan balances.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses, negative working capital, and lack of sufficient revenue.
• Uncertainty regarding the timing and ability to resolve the FDA Warning Letter and obtain FDA Premarket Approval (PMA) for Class III human surgical markets.
• Inability to secure adequate future financing on favorable terms, which could lead to dilution for existing shareholders if equity or convertible debt is issued.
• Reliance on a single operating segment (CelluSTAT hemostatic gauze) and the success of its Class III PMA application.
• Potential for increased borrowing costs due to rising interest rates and capital market volatility.
• Risk that the company may not identify suitable commercialization candidate(s) or enter into a sale, merger, or partnership transaction.
• Ineffectiveness of disclosure controls and procedures.

Future Outlook

The company is continuing its path to seek FDA Premarket Approval (PMA) for its CelluSTAT Hemostatic Gauze products for U.S. Class III human surgical markets, despite recent setbacks including an unresolved FDA Warning Letter and disapproval of a new clinical trial application. It does not intend to pursue full commercialization independently or remain an independent company long-term, actively evaluating options such as a sale, merger, or commercial partnerships with industry leaders. The timing for resolving the FDA Warning Letter and securing PMA approval remains uncertain.

Management Comments

• We are continuing on our path to seek FDA Premarket Approval (PMA) for our CelluSTAT Hemostatic Gauze products to implement our business strategy.
• Management is unable to predict if or when a Covered Transaction or Triggering Event under the RSU Agreements governing the restricted stock units will occur.
• We do not intend to pursue the full commercialization of our products independently nor to remain an independent company in the long term.
• Options under consideration include (i) a sale or merger of the Company with an industry leader in the wound care and surgical device sectors, which may include a pre-sale collaboration on commercialization and distribution and (ii) one or more commercial partnerships with established market participants, without any specific, associated sale or merger transaction.
• The Company has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company's products and business strategy.
• As of June 30, 2025, the Chief Executive Officer and Principal Financial Officer carried out an assessment of the effectiveness of the design and operation of our disclosure controls and procedures and concluded that the Company's disclosure controls and procedures were not effective.

Industry Context

The company operates in the highly regulated medical device and wound care sectors, specifically targeting the hemostatic agent market. Its primary focus on obtaining Class III FDA PMA for surgical use indicates an ambition to compete in a segment with fewer competitors and premium pricing, currently dominated by established players like Ethicon (Surgicel Original). The ongoing regulatory challenges, particularly the FDA Warning Letter and IDE disapproval, highlight the significant hurdles and lengthy timelines associated with bringing new Class III devices to market, which is a common challenge for smaller, development-stage companies in this industry.

Comparison to Industry Standards

• The company's lack of revenue and recurring net losses are significantly below industry standards for commercialized medical device companies.
• The reliance on external financing and the "going concern" warning are typical for early-stage biotech/medtech companies but indicate a high-risk profile compared to established industry players.
• The FDA's Bioresearch Monitoring Program (BIMO) inspection and subsequent Warning Letter, citing violations in a prior clinical trial, suggest a deviation from the rigorous quality and procedural standards expected in the medical device industry, especially for Class III devices.
• The company's product, CelluSTAT, showed statistically superior performance to Ethicon's Surgicel Original in a 2019 clinical trial, suggesting strong product potential if regulatory hurdles are overcome. However, the FDA's request for more data and the disapproval of the IDE application indicate that the product has not yet met the full regulatory bar for broader surgical use, unlike fully approved competitors.
• The company's strategy to seek a sale, merger, or partnership rather than independent commercialization aligns with a common path for smaller medtech firms that develop promising technology but lack the capital and infrastructure for large-scale market entry.

Management Changes

Corporate Governance

Legal Proceedings

• None reported.

Related Party Transactions

• Convertible notes payable to related parties totaled $500,000 as of June 30, 2025.
• Brian Thom (CEO) has a convertible note of $372,000 (converted from a loan) with 13% interest, maturity extended to December 31, 2026. Accrued interest is $174,391.
• Robert Denser (Director) has a convertible note of $93,000 with 13% interest, maturity extended to December 31, 2026. Accrued interest is $37,720.
• The CEO advanced $20,000 to the company for operating expenses during the six months ended June 30, 2025, which was subsequently repaid in full.

Stakeholder Impact

• Shareholders: Significant dilution risk from future equity raises, substantial doubt about going concern, and uncertainty regarding FDA approval and strategic transactions. Existing shares are subject to potential value erosion due to ongoing losses and regulatory hurdles.
• Employees: Potential job insecurity due to the company's "going concern" issues and lack of revenue. Management changes at the executive level may create instability.
• Customers: Current commercial activities are paused, limiting product availability. Future availability of Class III product is uncertain due to regulatory delays.
• Suppliers/Creditors: Increased risk due to negative working capital, recurring losses, and the "going concern" warning, potentially impacting payment terms or willingness to extend credit.
• Regulatory Authorities: Ongoing engagement with the FDA due to a Warning Letter and IDE disapproval, requiring significant attention and resources to address compliance issues.

Next Steps

• Resolve the FDA Warning Letter regarding the 2019 clinical trial violations.
• Seek a path to timely approval of a new Investigational Device Exemption (IDE) and commencement of the 27-subject clinical trial.
• Engage with the FDA, potentially identifying an alternative sponsor for the clinical study.
• Evaluate and pursue strategic options, including a sale, merger, or commercial partnerships, in anticipation of FDA Class III PMA.
• Identify and contract suitable surgical sites for the proposed supplemental clinical study.
• Enroll patients, collect data, and analyze results for the supplemental clinical study.
• Address the ineffectiveness of disclosure controls and procedures.
• Seek suitable replacement candidates for the Vice President of Finance and Principal Financial Officer positions.

Key Dates

Recommendation

The company faces severe financial distress with minimal cash reserves ($225), recurring substantial net losses, and a significant negative working capital position, leading to a 'going concern' warning. Critically, its path to commercializing its key product, CelluSTAT, in the lucrative Class III surgical market is severely hampered by an unresolved FDA Warning Letter citing clinical trial violations and the subsequent disapproval of a crucial new clinical trial application. While the product shows promise and the company is exploring strategic alternatives like a sale or merger, the immediate regulatory and financial hurdles are immense and highly uncertain. The ineffectiveness of disclosure controls further compounds the risk. Given the high probability of continued losses, significant dilution, and the uncertain regulatory timeline, the stock presents an extremely high risk with little near-term upside potential.

Keywords

Hemostatic Gauze, CelluSTAT, FDA PMA, Class III Medical Device, Wound Care, Surgical Hemostat, Medical Technology, Bioresearch Monitoring Program, SEC 10-Q, Going Concern, Clinical Trials, Medical Device Approval